Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy
Authors:
- Michael H. DavidsonMDMichael H. Davidson
- 17 April 2008
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 101 (8) , S27-S35
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsNew England Journal of Medicine, 2007
- Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyThe Lancet, 2006
- Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin TherapyJACC, 2006
- High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial InfarctionThe IDEAL Study: A Randomized Controlled TrialJAMA, 2005
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary SyndromesJAMA, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002